Posted by Michael Wonder on 29 Mar 2020
Pharma’s future blockbusters laid up with coronavirus
27 March 2020 - Normally a haven during downturns, pharmaceuticals will see forthcoming products delayed as pandemic disrupts or delays clinical trials.
Pharmaceutical companies tend to be relatively safe places to invest during economic shocks, but even they aren’t immune to the pinch from COVID-19.
After all, demand for prescription medication is mostly insensitive to the economy, and seasonality plays a limited role in the business.
